Gastrointestinal Stromal Tumors Treatment (PDQ®)
Imatinib can be monitored for response using 18F‑FDG PET as early as 24 hours after the first dose, allowing earlier detection of tumor response or resistance than with CT imaging.
This PDQ cancer information summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about the treatment of gastrointestinal stromal tumors. It does not provide formal guidelines or recommendations for making health care decisions.
Early identification of treatment efficacy or resistance with PET imaging can enable clinicians to adjust management promptly, potentially improving outcomes for patients with unresectable, metastatic, or recurrent GIST.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)